NovaBay Shareholder Information .... Investor O
Post# of 50
NovaBay Shareholder Information ....
Investor Overview
NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented topical Aganocide® compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's topical Aganocide compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital infections, chronic non-healing wounds, UCBE and onychomycosis.
NovaBay has entered into and recently expanded an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications.
Transfer Agent
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. with the following contact information:
For standard US postal mail
Computershare Trust Company, N.A.
Po Box 43070
Providence, RI 02940-3070
For overnight/express delivery
Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
For DWAC instructions provided to brokers
FAST Transfer Agent number – 50173
Telephone and Fax
Toll free in the US +1 800 962 4284
Telephone +1 303-262-0600
Fax +1 303-262-0700
Website
www.computershare.com
eMail inquiries
web.queries@computershare.com
Investor Relations contacts
Theresa Granados
(510) 899-8870
Email Theresa
Events
May 18, 2011
Archive of Conference call Re: Results from Phase 2 Clinical Study for the Treatment of Adenoviral Conjunctivitis
Click Here To Listen
September 21, 2010
Behzad Khosrovi, M.A., Ph.D. of NovaBay Interviewed on HealthRadio.net about Antibiotic Resistance
July 21, 2010
Archive of Conference call Re: Impetigo Clinical Trial Results
Click Here To Listen
July 10-14, 2010
Ron Najafi, NovaBay CEO, to be Plenary Speaker at Controlled Release Society (CRS) Annual Meeting
April 19, 2010
Archive of Conference call Re: CAUTI Trial Pipeline Update
Click Here To Listen
March 25, 2010
Catheter-Associated Urinary Tract Infection Expert, David Stickler, Interviewed
Click Here To Listen
February 09, 2010
NovaBay CEO Ron Najafi Presents at BIO CEO & Investor Conference
Click Here To Listen
January 10, 2010
Founding Director of UCLA's Urological Center and NovaBay SAB Member, Bernard Churchill, M.D., Interviewed
Click Here to Listen
December 22, 2009
World-Renowned Biofilm Expert and NovaBay SAB Member, William Costerton, Ph.D., Interviewed
Click Here to Listen
March 25, 2009
NovaBay and Galderma enter into Global Agreement to Develop and Commercialize NovaBay’s Novel Aganocide Drugs for Major Dermatological Conditions
View this webcast Wednesday, March 25, 2009 at 8:00AM PT
August 7, 2008
NovaBay Pharmaceuticals, Inc. Featured on KGO-TV San Francisco
The video can be viewed here
Corporate Governance
NovaBay is committed to good governance and business practices. High standards of corporate governance are a priority at NovaBay. The Board and management team believe that commitment to excellence and integrity is essential to the long-term success of the Company and to sustaining strong stakeholder relationships. NovaBay uses a variety of policies, programs and practices to manage corporate governance.
Code of Business Conduct and Ethics
Audit Committee Charter
Whistleblower Policy
Corporate Governance Guidelines
Compensation Committee Charter
Nomination and Corporate Governance Committee Charter
Composition of Board Committees
(0)
(0)